Pembrolizumab: all 1,753 studies that test it

Page 8 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsTerminatedNCT03311334Phase 1/2Results posted
• Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT03310957Phase 1/2Results posted
• Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung CarcinomaTerminatedNCT03307759Phase 1Results posted
• A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic MelanomaTerminatedNCT03301636Phase 2Results posted
• Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene MutationsCompletedNCT03299088Phase 1Results posted
• Pembrolizumab in Elderly Patients With Advanced Lung CancerCompletedNCT03293680Phase 2Results posted
• Epacadostat and Pembrolizumab in Patients With GISTTerminatedNCT03291054Phase 2Results posted
• Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine TumorsCompletedNCT03290079Phase 2Results posted
• Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial CarcinomaTerminatedNCT03287050Phase 2Results posted
• Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With PembrolizumabTerminatedNCT03286114Phase 1Results posted
• Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)CompletedNCT03284424Phase 2Results posted
• Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade MeningiomaActive, not recruitingNCT03279692Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Combination With RomidepsinActive, not recruitingNCT03278782Phase 1/2Results posted
• Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV MelanomaCompletedNCT03276832Early Phase 1Results posted
• Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRCCompletedNCT03274804Phase 1Results posted
• Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient TumorsCompletedNCT03274661Phase 2Results posted
• Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT03267888Phase 1/2Results posted
• Azacitidine and Pembrolizumab in Pancreatic CancerCompletedNCT03264404Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedNCT03260894Phase 3Results posted
• Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney CancerTerminatedNCT03260504Phase 1Results posted
• Pembrolizumab + Idelalisib for Lung Cancer StudyTerminatedNCT03257722Phase 1/2Results posted
• Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell LymphomasCompletedNCT03255018Phase 2Results posted
• Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)TerminatedNCT03249792Phase 1Results posted
• Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair DefectsCompletedNCT03248570Phase 2Results posted
• Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted AgentsCompletedNCT03242915Phase 2Results posted
• Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)TerminatedNCT03241927Phase 2Results posted
• PD-1 Inhibition to Determine CNS Reservoir of HIV-InfectionCompletedNCT03239899Phase 1Results posted
• Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedNCT03239145Phase 1Results posted
• Focused Ultrasound and Pembrolizumab in Metastatic Breast CancerTerminatedNCT03237572Phase 1Results posted
• Phase Ib of L-NMMA and PembrolizumabCompletedNCT03236935Phase 1Results posted
• Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasTerminatedNCT03233724Phase 1/2Results posted
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaCompletedNCT03229278Phase 1Results posted
• PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin LymphomaActive, not recruitingNCT03226249Phase 2Results posted
• Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & TaxanesCompletedNCT03222856Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)CompletedNCT03221426Phase 3Results posted
• Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast CancerCompletedNCT03213041Phase 2Results posted
• Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver CancerCompletedNCT03211416Phase 1/2Results posted
• Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT03210662Phase 2Results posted
• Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03204188Phase 2Results posted
• Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced MelanomaCompletedNCT03200847Phase 1/2Results posted
• Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung CancerCompletedNCT03197467Phase 2Results posted
• Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.CompletedNCT03197389Early Phase 1Results posted
• Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric CancerCompletedNCT03196232Phase 2Results posted
• Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine CarcinomaTerminatedNCT03190213Phase 2Results posted
• First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)CompletedNCT03189719Phase 3Results posted
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03184571Phase 2Results posted
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBCTerminatedNCT03184558Phase 2Results posted
• Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin LymphomaActive, not recruitingNCT03179917Phase 2Results posted
• Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)CompletedNCT03179436Phase 1/2Results posted
• Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)TerminatedNCT03175172Phase 2Results posted
• Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple MyelomaTerminatedNCT03168438Phase 1Results posted
• Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT03167151Phase 1/2Results posted
• Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of SorafenibCompletedNCT03163992Phase 2Results posted
• Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow LymphoblastsCompletedNCT03160079Phase 1/2Results posted
• Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the LungCompletedNCT03157089Phase 2Results posted
• Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the PancreasCompletedNCT03153410Early Phase 1Results posted
• Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.Active, not recruitingNCT03150329Phase 1Results posted
• Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03149822Phase 1/2Results posted
• A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix CancerTerminatedNCT03144466Phase 1Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)CompletedNCT03142334Phase 3Results posted
• A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT03126591Phase 1Results posted
• Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic SarcomaCompletedNCT03123276Phase 1/2Results posted
• A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell CarcinomaTerminatedNCT03123055Phase 1/2Results posted
• Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal CancersTerminatedNCT03122548Phase 2Results posted
• Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast CancerCompletedNCT03121352Phase 2Results posted
• A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary CancersTerminatedNCT03115801Phase 2Results posted
• P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03113487Phase 2Results posted
• Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)CompletedNCT03111732Phase 2Results posted
• Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaTerminatedNCT03108495Phase 2Results posted
• Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerCompletedNCT03106415Phase 1/2Results posted
• Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)TerminatedNCT03099161Phase 1Results posted
• Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal CancerCompletedNCT03095781Phase 1Results posted
• Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall DiseaseCompletedNCT03095352Phase 2Results posted
• Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic SyndromeStatus unknownNCT03094637Phase 2Results posted
• Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPCCompletedNCT03093428Phase 2Results posted
• Dendritic Cell Vaccination in Patients With Advanced MelanomaCompletedNCT03092453Phase 1Results posted
• Pembrolizumab in Patients With Leptomeningeal DiseaseTerminatedNCT03091478Phase 2Results posted
• Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging BiomarkerCompletedNCT03089606Phase 2Results posted
• Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung CancerCompletedNCT03087760Phase 2Results posted
• Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHNActive, not recruitingNCT03085719Phase 2Results posted
• Phase II Trial of Continuation Therapy in Advanced NSCLCCompletedNCT03083808Phase 2Results posted
• Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaCompletedNCT03082534Phase 2Results posted
• Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT03077828Phase 2Results posted
• Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompletedNCT03072160Phase 2Results posted
• A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingNCT03069378Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)CompletedNCT03066778Phase 3Results posted
• PD-1 Inhibition in Advanced Myeloproliferative NeoplasmsCompletedNCT03065400Phase 2Results posted
• Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)CompletedNCT03064490Phase 2Results posted
• Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial SarcomaCompletedNCT03063632Phase 2Results posted
• Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Phase 3Results posted
• The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and NeckCompletedNCT03057613Phase 2Results posted
• Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for SarcomaCompletedNCT03056001Phase 2Results posted
• Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BCTerminatedNCT03051672Phase 2Results posted
• A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast CancerCompletedNCT03051659Phase 2Results posted
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTerminatedNCT03050060Phase 2Results posted
• Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475CompletedNCT03049618Phase 2Results posted
• Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by SurgeryStatus unknownNCT03044730Phase 2Results posted
• Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT03043664Phase 1/2Results posted
• Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)CompletedNCT03040999Phase 3Results posted
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)CompletedNCT03036488Phase 3Results posted

← Pembrolizumab overview